Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT02201056
PHASE1
Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
Sponsor: Takeda
View on ClinicalTrials.gov
Summary
The purpose of this study is to characterize the safety and tolerability profile of TAK-935 in healthy participants when administered as a single dose of oral solution at escalating dose levels.
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2014-07
Completion Date
2015-07
Last Updated
2026-09-15
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
TAK-935
TAK-935 oral solution
DRUG
Placebo
TAK-935 placebo-matching oral solution
Locations (1)
Lincoln, Nebraska, United States